Oncology & Epidemiology & Lung Cancer
Conditions
Keywords
lung cancer epidemiology algeria registry
Brief summary
National, prospective, multicentric, non-interventional registry-based study, conducted among oncologists, pulmonologists in community and university hospitals, from the public sector in Algeria. The study will collect information on the characteristics, and lung carcinomas patterns of patients whose lung cancer diagnosis was confirmed by a pathologist during the study period.
Detailed description
The study consists of: * All patients meeting inclusion/exclusion criteria presenting to their oncologists/pulmonologists for a routine visit during recruitment period will be sequentially asked to participate to the study. * The patients who do not consent will only be reported as new case of lung cancer for the incidence study. The patients who consent to participate to the study will perform four in-hospital visits (Inclusion visit, visit at 3, 6 and 12 months). In addition to the 4 visits, a phone contact with the patients every 6 months at years 2,3, 4 and 5 will be done by the investigator or one of his/her authorised representative or the CRO or during a routine visit to the investigator, to check the patient's survival status. THE STUDY DURATION 72 MONTHS
Interventions
OTHERNIS observational stud
NIS observational study : Epidemiologic registry
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist * Aged at least18 years at diagnosis * Patients who provide their informed consent form
Exclusion criteria
* Patients who did not provide the informed consent form * Patients with a mental or psychological disorder according to their treating clinicians
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence of lung cancer | 12 months of recruitment period | incidence of lung cancer, all types, stages and ages combined, in men and women newly diagnosed with lung cancer in Algeria over 12 months of recruitment period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence of newly diagnosed lung cancer | 12 month period | 1\) To characterise the incidence of newly diagnosed lung cancer in Algeria in a 12 month period according to patient and disease characteristics (Wilaya, sex, age, lung cancer type, stage disease and smoking status). |
| survival | at 12, 24, 36, 48 and 60 months of follow-up. | — |
| quality of life -EORTC QLQ-C30 | baseline, 3, 6 and 12 months follow-up. | To evaluate the quality of life of patients diagnosed with lung cancer in Algeria according to EORTC QLQ-C30 ) |
| Quality Of Life-EORTC QLQ- LC13 | baseline, 3, 6 and 12 months follow-up. | To evaluate the quality of life of patients diagnosed with lung cancer in Algeria according to EORTC QLQ- LC13 |
Countries
Algeria
Outcome results
None listed